File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s10637-009-9269-x
- Scopus: eid_2-s2.0-77956620903
- PMID: 19471857
- WOS: WOS:000277942700005
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines
Title | The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines | ||||
---|---|---|---|---|---|
Authors | |||||
Keywords | AKT mTOR Nasopharyngeal carcinoma RAD001 (everolimus) | ||||
Issue Date | 2010 | ||||
Publisher | Springer New York LLC. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0167-6997 | ||||
Citation | Investigational New Drugs, 2010, v. 28 n. 4, p. 413-420 How to Cite? | ||||
Abstract | Phosphorylated (pi-) protein kinase B (AKT) is commonly expressed in nasopharyngeal carcinoma (NPC) cell lines and tissues, suggesting the involvement of AKT-mammalian target of rapamycin (mTOR) signaling in NPC carcinogenesis. This study evaluated the activity of an mTOR inhibitor, RAD001 (Everolimus, Novartis Pharma AG, Switzerland), in 5 NPC cell lines (HK1, HONE-1, CNE-1, CNE-2, C666-1), 2 cisplatin-resistant NPC cell lines and their respective parental cell lines (HK1-LMP1, HONE-1-EBV). RAD001 inhibited cell growth in a dose-dependent manner at nanomolar concentrations in all cell lines. HONE-1 was most sensitive to RAD001 (IC50=0.63 nM, 60% maximal inhibition), while Het-1A (a normal esophageal epithelial cell line) was relatively resistant. No consistent relationship between sensitivity to RAD001 and basal expression of pi-mTOR and pi-p70S6 Kinase-1 (p70S6K) was found. Exposure to RAD001 at picomolar concentrations for 48 h resulted in reduction of pi-mTOR and pip70S6K1 expression, but increase in pi-AKT (Ser473) expression in HONE-1 and CNE-1 cell lines. RAD001 significantly induced apoptosis in HONE-1 cells, but has no effect on cell cycle progression. RAD001 exerted an additive to synergistic effect on cisplatin-induced growth inhibition in CNE-1 and HONE-1 cells, and could inhibit the growth of both cisplatin-resistant and cisplatin-sensitive NPC cell lines. In summary, combination of RAD001 and cisplatin maybe a useful therapeutic strategy in NPC. AKT upregulation following RAD001 treatment suggests the presence of a feedback loop on AKT signaling in NPC which warrants further investigation. © Springer Science + Business Media, LLC 2009. | ||||
Persistent Identifier | http://hdl.handle.net/10722/124476 | ||||
ISSN | 2023 Impact Factor: 3.0 2023 SCImago Journal Rankings: 1.086 | ||||
ISI Accession Number ID |
Funding Information: This study was supported in part by Li Ka Shing Institute for the Health Science, Chinese University of Hong Kong. Reprint requests should be sent to the corresponding author. The authors declare no conflict of interest with this manuscript. Result of this study was presented in part at the Annual Meeting of the American Association of Cancer Research, San Diego, CA, 2008. We thank Dr S. Hardikar and Novartis Pharmaceuticals Corporation for providing RAD001 in this study. | ||||
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ma, BBY | en_HK |
dc.contributor.author | Lui, VWY | en_HK |
dc.contributor.author | Hui, EP | en_HK |
dc.contributor.author | Lau, CPY | en_HK |
dc.contributor.author | Ho, K | en_HK |
dc.contributor.author | Ng, MHL | en_HK |
dc.contributor.author | Cheng, SH | en_HK |
dc.contributor.author | Tsao, SW | en_HK |
dc.contributor.author | Chan, ATC | en_HK |
dc.date.accessioned | 2010-10-31T10:36:33Z | - |
dc.date.available | 2010-10-31T10:36:33Z | - |
dc.date.issued | 2010 | en_HK |
dc.identifier.citation | Investigational New Drugs, 2010, v. 28 n. 4, p. 413-420 | en_HK |
dc.identifier.issn | 0167-6997 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/124476 | - |
dc.description.abstract | Phosphorylated (pi-) protein kinase B (AKT) is commonly expressed in nasopharyngeal carcinoma (NPC) cell lines and tissues, suggesting the involvement of AKT-mammalian target of rapamycin (mTOR) signaling in NPC carcinogenesis. This study evaluated the activity of an mTOR inhibitor, RAD001 (Everolimus, Novartis Pharma AG, Switzerland), in 5 NPC cell lines (HK1, HONE-1, CNE-1, CNE-2, C666-1), 2 cisplatin-resistant NPC cell lines and their respective parental cell lines (HK1-LMP1, HONE-1-EBV). RAD001 inhibited cell growth in a dose-dependent manner at nanomolar concentrations in all cell lines. HONE-1 was most sensitive to RAD001 (IC50=0.63 nM, 60% maximal inhibition), while Het-1A (a normal esophageal epithelial cell line) was relatively resistant. No consistent relationship between sensitivity to RAD001 and basal expression of pi-mTOR and pi-p70S6 Kinase-1 (p70S6K) was found. Exposure to RAD001 at picomolar concentrations for 48 h resulted in reduction of pi-mTOR and pip70S6K1 expression, but increase in pi-AKT (Ser473) expression in HONE-1 and CNE-1 cell lines. RAD001 significantly induced apoptosis in HONE-1 cells, but has no effect on cell cycle progression. RAD001 exerted an additive to synergistic effect on cisplatin-induced growth inhibition in CNE-1 and HONE-1 cells, and could inhibit the growth of both cisplatin-resistant and cisplatin-sensitive NPC cell lines. In summary, combination of RAD001 and cisplatin maybe a useful therapeutic strategy in NPC. AKT upregulation following RAD001 treatment suggests the presence of a feedback loop on AKT signaling in NPC which warrants further investigation. © Springer Science + Business Media, LLC 2009. | en_HK |
dc.language | eng | en_HK |
dc.publisher | Springer New York LLC. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0167-6997 | en_HK |
dc.relation.ispartof | Investigational New Drugs | en_HK |
dc.subject | AKT | en_HK |
dc.subject | mTOR | en_HK |
dc.subject | Nasopharyngeal carcinoma | en_HK |
dc.subject | RAD001 (everolimus) | en_HK |
dc.title | The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Tsao, SW:gswtsao@hkucc.hku.hk | en_HK |
dc.identifier.authority | Tsao, SW=rp00399 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1007/s10637-009-9269-x | en_HK |
dc.identifier.pmid | 19471857 | - |
dc.identifier.scopus | eid_2-s2.0-77956620903 | en_HK |
dc.identifier.hkuros | 182814 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-77956620903&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 28 | en_HK |
dc.identifier.issue | 4 | en_HK |
dc.identifier.spage | 413 | en_HK |
dc.identifier.epage | 420 | en_HK |
dc.identifier.isi | WOS:000277942700005 | - |
dc.publisher.place | United States | en_HK |
dc.identifier.scopusauthorid | Ma, BBY=7403301016 | en_HK |
dc.identifier.scopusauthorid | Lui, VWY=7004231347 | en_HK |
dc.identifier.scopusauthorid | Hui, EP=7005081895 | en_HK |
dc.identifier.scopusauthorid | Lau, CPY=36608195100 | en_HK |
dc.identifier.scopusauthorid | Ho, K=34971221500 | en_HK |
dc.identifier.scopusauthorid | Ng, MHL=35292609300 | en_HK |
dc.identifier.scopusauthorid | Cheng, SH=7404681588 | en_HK |
dc.identifier.scopusauthorid | Tsao, SW=7102813116 | en_HK |
dc.identifier.scopusauthorid | Chan, ATC=13404833700 | en_HK |
dc.identifier.citeulike | 4691549 | - |
dc.identifier.issnl | 0167-6997 | - |